ALX Oncology Holdings Inc
ALXO
ISIN null / Valor 55754366
ALX Oncology Holdings Inc
UMushroom community rating:
About company
ALX Oncology Holdings Inc is a clinical stage biotechnology company focused on developing innovative immuno-oncology therapies for cancer. The company's lead candidate, evorpacept, is designed to bind CD47 with greater affinity than natural SIRPα, aiming to block the "don't eat me" signal on cancer cells and activate the immune system to fight against cancer. ALX Oncology's strategy is to pursue evorpacept as a critical component for future combination treatments in oncology, leveraging the immune activation of widely used anti-cancer agents. With promising clinical results in multiple oncology indications, the company aims to address fundamental challenges in blocking CD47 and realize the full potential of this therapeutic target.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (08.11.2025):
ALX Oncology Holdings Inc reported its financial results for Q1 2025, highlighting significant progress in clinical development and a solid financial footing. The company achieved a reduction in R&D expenses while extending its cash runway into Q4 2026, alongside modest improvements in net loss, which underscores its strategic focus on advancing novel cancer therapies.
Cash Position & Runway
As of March 31, 2025, ALX Oncology Holdings Inc held $107.0 million in cash, cash equivalents, and investments, ensuring funding for planned operations into Q4 2026.
R&D Expense Reduction
R&D expenses for Q1 2025 decreased to $23.9 million from $31.7 million in Q1 2024, reflecting lower clinical and development manufacturing costs and reduced stock-based compensation associated with its clinical programs.
Increase in G&A Expenses
General and Administrative expenses increased to $7.9 million in Q1 2025, up from $6.0 million in the same quarter last year, driven primarily by an increase in personnel-related costs.
Net Loss Improvement
The GAAP net loss for Q1 2025 was recorded at ($30.8) million, or ($0.58) per share, improving from a net loss of ($35.6) million, or ($0.71) per share, in Q1 2024, with non-GAAP net loss at ($25.5) million compared to ($28.5) million previously.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
73 M
Market cap (USD)
167,667
Daily traded volume (Shares)
1.695 / 1.55
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Matthias Bittel
EQUITIES OF THE SAME SECTOR
